HRT Financial
GTBP icon

HRT Financial’s GT Biopharma GTBP Stock Holding History

HRT Financial’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-4,286
Closed -$52K – 5191
2026
Q2 		$52K Buy
+4,286
New +$43.5K ﹤0.01% 3766
2026
Q1 		– Sell
-471
Closed -$9K – 4155
2025
Q4 		$9K Buy
+471
New +$8.36K ﹤0.01% 3046
2024
Q1 		– Sell
-45
Closed -$8K – 2608
2023
Q4 		$8K Buy
+45
New +$8.22K ﹤0.01% 2096

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Arax Advisory Partners
Arax Advisory Partners Denver, Colorado $17.7B AUM 20.22% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Allworth Financial
Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

HRT Financial's GTBP Position: Q3 2026 in Review

HRT Financial sold out of GT Biopharma (GTBP) in Q3 2026, closing a stake of 4,286 shares — an estimated $52K sold.

HRT Financial first reported a position in GTBP in Q4 2023 and held it in 3 quarters. The position peaked at $52K in Q2 2026. 22 funds tracked by Wall St. Rank hold GTBP as of Q3 2026.

  • HRT Financial reported no remaining GT Biopharma position as of Q3 2026 after selling out during the quarter.
  • HRT Financial sold 4,286 GT Biopharma shares in Q3 2026, an estimated $52K.
  • HRT Financial first reported a position in GT Biopharma in Q4 2023 and held it in 3 quarters.
  • HRT Financial's GT Biopharma position peaked at $52K in Q2 2026.
  • 22 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2026.

Based on HRT Financial's 13F filing for Q3 2026, filed 13 Nov 2026.